Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10914728 | Molecular Oncology | 2015 | 11 Pages |
Abstract
The new age of Precision Cancer Medicine, with specific biomarkers being used to direct targeted agents, generally concerns only a subset of patients within a certain histopathologically defined tumor type. This paradigm is challenged by the need to perform widespread molecular screening in certified laboratories, with results available to clinicians within reasonable timeframe. Tumor heterogeneity and clonal evolution must be considered in the decision making process. Adaptive and innovative clinical trial designs exploring predictive algorithms and reconsideration of traditional efficacy endpoints are required to rapidly translate scientific discoveries into patient care. Furthermore, international collaboration in cancer research and open discussions on the availability of investigational agents will likely redefine the drug development and approval process in the coming years.
Keywords
CSCICGCFDAPrecision cancer medicineDCRTCGATGRTTGCtDNAEMAPCMNCICTCPFsEuropean Medicines agencyInvestigational Device ExemptionThe cancer genome atlasIDEprogression-free survivaloverall survivalRECISTTargeted therapyFood and Drug AdministrationColorectal cancerNSCLCNon-small cell lung cancercancer stem cellClinical trial designGistResponse Evaluation Criteria in Solid TumorsNational Cancer InstituteTumor growth rateDisease control rateWINCatalogue of Somatic Mutations in CancerCOSMICCRCInternational Cancer Genome Consortiumcirculating tumor DNAcirculating tumor cell
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Rodrigo Dienstmann, Jordi Rodon, Josep Tabernero,